A Study to Test the Efficacy and Safety of Bimekizumab in Study Participants
With Moderate to Severe Hidradenitis Suppurativa
(BE HEARD II)
Recruitment Status: recruiting as of August 2020
Estimated Completion Date: May of 2023
Sponsors and Collaborators: UCB Biopharma SRL
Information provided by (Responsible Party): UCB Biopharma SRL
Brief Summary: The purpose of the study is to test the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS).
Please link for complete details https://clinicaltrials.gov/ct2/show/NCT04242498
Locations: multiple locations please refer to link above for further information.
Contact: UCB Cares 1844599 ext 2273 UCBCares@ucb.com